Clinical outcomes in patients with early non-small-cell lung cancer treated surgically in Bogota (Colombia)

被引:0
|
作者
Alvarado-Sarzosa, Fernando [1 ]
Martinez-Jaramillo, Stella Isabel [2 ,3 ]
Hellal, Luis Gerardo Garcia-Herreros- [4 ]
Beltran-Jimenez, Rafael Jose [5 ]
Zuluaga-Restrepo, Juan David [6 ]
Parra-Medina, Rafael [7 ]
Escobar-avila, Laura Lucia [8 ]
Toledo-Arenas, Jose Daniel [9 ]
Carvajal-Fierro, Carlos Andres [5 ]
机构
[1] Univ Bosque, Programa Posgrad Cirugia Torax, Inst Nacl Cancerol, Convenio Docencia Serv, Bogota, DC, Colombia
[2] Cirugia Torax, Clin Reina Sofia, Bogota, DC, Colombia
[3] Univ Bosque, Programa Especializac Cirugia Torax, Bogota, DC, Colombia
[4] Fdn Santa Fe Bogota, Cirugia Torax, Bogota, DC, Colombia
[5] Inst Nacl Cancerol, Unidad Func Cirugia Torax, Bogota, DC, Colombia
[6] Clin CES, Cirugia Torax, Medellin, Colombia
[7] Inst Nacl Cancerol, Grp Patol Oncol, Bogota, DC, Colombia
[8] Lab Patol, Clin Reina Sofia, Bogota, DC, Colombia
[9] Univ Bosque, Psiquiatria & Epidemiol, , D C, Bogota, DC, Colombia
来源
REVISTA COLOMBIANA DE CANCEROLOGIA | 2023年 / 27卷 / 02期
关键词
Carcinoma; non-small-cell lung; adenocarcinoma of lung; neoplasm staging; recurrence; VISCERAL PLEURAL INVASION; INTERNATIONAL ASSOCIATION; GRADING SYSTEM; AIR SPACES; CLASSIFICATION; ADENOCARCINOMA; RECURRENCE; EPIDEMIOLOGY; REVISION; PROPOSAL;
D O I
10.35509/01239015.904
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In Colombia, information is limited on the survival of patients with lung cancer treated in the early stages. Thus, this study aimed to analyze the clinical outcomes and factors associated with the prognosis of patients with non-small-cell lung cancer (NSCLC) treated surgically in three institutions in Bogota.Methods: Analytical, observational, retrospective, and multicenter study.Results: The study included 101 patients with a median age of 69 years (IQR 63-75); 56 were women (55.4%). Of the patients, 8 (7.9%) had pathological stage 0, 83 (82.2%) were in stage I and 10 (9.9%) in stage II. The 3-year disease-free survival (DFS) of patients with stages 0, I, and II was 100%, 97%, and 58%, respectively. The overall survival (OS) of all included patients at 3 years was 94%. The OS of patients with and without relapse was 78% and 96%. A statistically significant association was found between relapse and stage II (P<0.001), relapse and T3 (P=0.048), relapse and N1 (P<0.001), and relapse and visceral pleura invasion (P=0.002). The only association found with death was relapse (P=0.002).Conclusions: The pathological stage and some special TNM characteristics, such as T3 tumor, the presence of N1 disease, and visceral pleura invasion, were determining factors in DFS. In contrast, the only factor associated with worse OS was relapse.
引用
收藏
页码:240 / 250
页数:11
相关论文
共 50 条
  • [1] Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non-small-cell Lung Cancer
    Chen, Kezhong
    Chen, Haiqing
    Yang, Fan
    Sui, Xizhao
    Li, Xiao
    Wang, Jun
    CLINICAL LUNG CANCER, 2017, 18 (06) : E457 - E466
  • [2] Influence of biological markers on overall survival in surgically treated patients with non-small cell lung cancer
    Loncarevic, Olivera
    Loncarevic, Slobodan
    Vekic, Berislav
    Djukanovic, Leonida
    Vukovic, Jelena
    Rancic, Nemanja
    VOJNOSANITETSKI PREGLED, 2021, 78 (11) : 1155 - 1165
  • [3] Vascular invasion is an adverse prognostic factor in resected non-small-cell lung cancer
    Ramnefjell, Maria
    Aamelfot, Christina
    Helgeland, Lars
    Akslen, Lars A.
    APMIS, 2017, 125 (03) : 197 - 206
  • [4] Imaging surveillance and survival for surgically resected non-small-cell lung cancer
    Backhus, Leah M.
    Farjah, Farhood
    Liang, Chao-Kang Jason
    He, Hao
    Varghese, Thomas K., Jr.
    Au, David H.
    Flum, David R.
    Zeliadt, Steven B.
    JOURNAL OF SURGICAL RESEARCH, 2016, 200 (01) : 171 - 176
  • [5] Prognostic gene signatures for non-small-cell lung cancer
    Boutros, Paul C.
    Lau, Suzanne K.
    Pintilie, Melania
    Liu, Ni
    Shepherd, Frances A.
    Der, Sandy D.
    Tsao, Ming-Sound
    Penn, Linda Z.
    Jurisica, Igor
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (08) : 2824 - 2828
  • [6] Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
    Paz-Ares, Luis
    Soulieres, Denis
    Melezinek, Ivan
    Moecks, Joachim
    Keil, Lorenz
    Mok, Tony
    Rosell, Rafael
    Klughammer, Barbara
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (1-2) : 51 - 69
  • [7] Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab
    Inoue, Takako
    Tamiya, Motohiro
    Tamiya, Akihiro
    Nakahama, Kenji
    Taniguchi, Yoshihiko
    Shiroyama, Takayuki
    Isa, Shin-ichi
    Nishino, Kazumi
    Kumagai, Toru
    Kunimasa, Kei
    Kimura, Madoka
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Atagi, Shinji
    Imamura, Fumio
    CLINICAL LUNG CANCER, 2018, 19 (02) : E171 - E176
  • [8] Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non-Small-Cell Lung Cancer
    Liang, Wenhua
    Zhang, Li
    Jiang, Gening
    Wang, Qun
    Liu, Lunxu
    Liu, Deruo
    Wang, Zheng
    Zhu, Zhihua
    Deng, Qiuhua
    Xiong, Xinguo
    Shao, Wenlong
    Shi, Xiaoshun
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) : 861 - +
  • [9] Non-small cell lung cancer in surgically treated women
    Rena, Ottavio
    Massera, Fabio
    Boldorini, Renzo
    Papalia, Esther
    Turello, Davide
    Davoli, Fabio
    Baietto, Guido
    Roncon, Alberto
    Robustellini, Mario
    Casadio, Caterina
    TUMORI JOURNAL, 2013, 99 (06): : 661 - 666
  • [10] Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
    Putzu, Carlo
    Cortinovis, Diego Luigi
    Colonese, Francesca
    Canova, Stefania
    Carru, Ciriaco
    Zinellu, Angelo
    Paliogiannis, Panagiotis
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (09) : 1349 - 1353